Please login to the form below

Not currently logged in
Email:
Password:

T-Vec

This page shows the latest T-Vec news and features for those working in and with pharma, biotech and healthcare.

Boehringer bolts on another immuno-oncology company

Boehringer bolts on another immuno-oncology company

The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from ... Oncolytic virus-based therapies are

Latest news

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    an inflammatory reaction in the tumours, while avelumab take the brake off a T-cell mediated immune response in a double-whammy against the cancer, according to Vyriad’s chief executive ... The first and so far only therapy of this type to reach the

  • Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

    This form of immuno-oncology has been spearheaded by Amgen, whose Imlygic (talimogene laherparepvec or T-Vec) was approved by the FDA last year, although it was not the first oncolytic

  • Amgen gets FDA nod for virus-based melanoma therapy Amgen gets FDA nod for virus-based melanoma therapy

    Imlygic (talimogene laherparepvec or T-Vec) is a genetically modified live Herpes simplex virus that is designed to infect and destroy melanoma lesions in the skin and lymph nodes that cannot

  • Amgen’s immuno-oncology drug scores in skin cancer Amgen’s immuno-oncology drug scores in skin cancer

    Talimogene Laherparepvec (or T-Vec), which works as an investigational oncolytic immunotherapy, was compared to those who received granulocyte-macrophage colony-stimulating factor (GM-CSF). . ... Amgen is already conducting trials of T-Vec alongside

  • FDA panel backs Amgen's T-Vec for melanoma FDA panel backs Amgen's T-Vec for melanoma

    The panel also had doubts about T-Vec's effect on patient survival but concluded it had a sufficiently favourable risk-benefit profile to warrant approval. ... Amgen is already conducting trials of T-Vec alongside Merck's Keytruda (pembrolizumab).

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics